Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

352 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD33 Delineates Two Functionally Distinct NK Cell Populations Divergent in Cytokine Production and Antibody-Mediated Cellular Cytotoxicity.
Hejazi M, Zhang C, Bennstein SB, Balz V, Reusing SB, Quadflieg M, Hoerster K, Heinrichs S, Hanenberg H, Oberbeck S, Nitsche M, Cramer S, Pfeifer R, Oberoi P, Rühl H, Oldenburg J, Brossart P, Horn PA, Babor F, Wels WS, Fischer JC, Möker N, Uhrberg M. Hejazi M, et al. Among authors: pfeifer r. Front Immunol. 2022 Jan 4;12:798087. doi: 10.3389/fimmu.2021.798087. eCollection 2021. Front Immunol. 2022. PMID: 35058934 Free PMC article.
A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy.
Bari R, Granzin M, Tsang KS, Roy A, Krueger W, Orentas R, Schneider D, Pfeifer R, Moeker N, Verhoeyen E, Dropulic B, Leung W. Bari R, et al. Among authors: pfeifer r. Front Immunol. 2019 Aug 22;10:2001. doi: 10.3389/fimmu.2019.02001. eCollection 2019. Front Immunol. 2019. PMID: 31507603 Free PMC article.
Corrigendum: A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy.
Bari R, Granzin M, Tsang KS, Roy A, Krueger W, Orentas R, Schneider D, Pfeifer R, Moeker N, Verhoeyen E, Dropulic B, Leung W. Bari R, et al. Among authors: pfeifer r. Front Immunol. 2019 Dec 4;10:2784. doi: 10.3389/fimmu.2019.02784. eCollection 2019. Front Immunol. 2019. PMID: 31839796 Free PMC article.
Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia.
Albinger N, Pfeifer R, Nitsche M, Mertlitz S, Campe J, Stein K, Kreyenberg H, Schubert R, Quadflieg M, Schneider D, Kühn MWM, Penack O, Zhang C, Möker N, Ullrich E. Albinger N, et al. Among authors: pfeifer r. Blood Cancer J. 2022 Apr 13;12(4):61. doi: 10.1038/s41408-022-00660-2. Blood Cancer J. 2022. PMID: 35418180 Free PMC article.
Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers.
Fischer-Riepe L, Kailayangiri S, Zimmermann K, Pfeifer R, Aigner M, Altvater B, Kretschmann S, Völkl S, Hartley J, Dreger C, Petry K, Bosio A, von Döllen A, Hartmann W, Lode H, Görlich D, Mackensen A, Jungblut M, Schambach A, Abken H, Rossig C. Fischer-Riepe L, et al. Among authors: pfeifer r. Clin Cancer Res. 2024 Apr 9:OF1-OF14. doi: 10.1158/1078-0432.CCR-23-3157. Online ahead of print. Clin Cancer Res. 2024. PMID: 38593230
Ganglioside SSEA-4 in Ewing sarcoma marks a tumor cell population with aggressive features and is a potential cell-surface immune target.
Jamitzky S, Altvater B, Krekeler C, Hoen L, Brandes C, Ebbinghaus J, Richter L, Kosel L, Ochs L, Farwick N, Urban K, Kluge L, Bücker L, Görlich D, Johnston ICD, Pfeifer R, Hartmann W, Rossig C, Kailayangiri S. Jamitzky S, et al. Among authors: pfeifer r. Sci Rep. 2024 May 24;14(1):11935. doi: 10.1038/s41598-024-62849-8. Sci Rep. 2024. PMID: 38789477 Free PMC article.
352 results